MARKER THERAPEUTICS, INC. Deferred Revenue
MARKER THERAPEUTICS, INC. (MRKR) had Deferred Revenue of $974.80 thousand as of 2025-12-31, per its 10-K filed 2026-03-18.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DeferredRevenueCurrent · last filed 2026-03-18
- 2025-12-31: Deferred Revenue, Current $974.80K.
- 2025-09-30: Deferred Revenue, Current $1.35M.
- 2025-06-30: Deferred Revenue, Current $1.35M.
- 2023-09-30: Deferred Revenue, Current $107.53K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2025-12-31 | $974.80K 10-K · filed 2026-03-18 |
| 2025-09-30 | $1.35M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.35M 10-Q · filed 2025-08-14 |
| 2023-09-30 | $107.53K 10-Q · filed 2023-11-09 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-22 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-10 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-11 |
| 2022-03-31 | $181.86K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $1.15M 10-K · filed 2023-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |